CholestasisDoc

Honoured to speak on #FMT #LBPs at the #EHMSG meeting today in session with Nicolas Benech and Jens Walter. Thanks to Gianluca Ianiro for organising, and for even getting a @nobelprize.bsky.social winner for Physics to speak to us, Giorgio Parisi! @imperialmdr.bsky.social #microbiomeclinicians

11.09.2025 15:00 — 👍 6    🔁 2    💬 2    📌 0

Infographic panel for the Lancet Diabetes & Endocrinology Commission on diagnosing clinical obesity.

🆕 Global Commission proposes overhaul of obesity diagnosis – going beyond BMI to define when obesity is a disease.

Find out more: hubs.li/Q030v_j_0

15.01.2025 07:53 — 👍 36    🔁 16    💬 2    📌 10

New research - Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial

www.thelancet.com/journals/lan...

#GastroSky #OncSky #MedSky @oncoalert.bsky.social

15.01.2025 06:07 — 👍 9    🔁 5    💬 0    📌 2

And why would Mox and Jericho team together?! Surely Mox’s current position makes him against Jericho nonsense?!

14.01.2025 20:26 — 👍 2    🔁 0    💬 1    📌 0

But the problem is that “why would Hobbs AND Cope be on a match against Mox, if the former were champion? The graphic basically tells viewers that Cope is still going to be gunning for “Mox’s” championship.

14.01.2025 20:26 — 👍 0    🔁 0    💬 0    📌 0

Because why would Hobbs be in a 12-man with Cope, against Mox, if he was winning the title Wednesday?

The 12-man basically tells the viewer that Mox is gonna face Cope for the championship at the next PPV.

I’d rather be happy than right. So I hope AEW prove me wrong and belt Hobbs tomorrow.

14.01.2025 20:24 — 👍 0    🔁 0    💬 0    📌 0

Well, not after telegraphing the finish with the god awful 12man planned for Collision next Saturday.

13.01.2025 18:20 — 👍 0    🔁 0    💬 2    📌 0

FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial Introduction Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). The strong association between gut and liver inflammation has driven...

Pleased that #FARGO - a randomised, multicentre, placebo-controlled phase IIa trial of #FMT to treat #PSC - is running and recruiting. Have a look at the protocol paper out now in #BMJOpen: doi.org/10.1136/bmjo... @pscsupport.bsky.social @cholestasisdoc.bsky.social

07.01.2025 07:30 — 👍 23    🔁 10    💬 1    📌 2

New from us: our trial protocol for faecal microbiota transplantation to treat people living with PSC and IBD.

Actively recruiting!
@bhmullish.bsky.social @nabilquraishi.bsky.social @alanmcn1.bsky.social @pscsupport.bsky.social

bmjopen.bmj.com/content/bmjo...

07.01.2025 10:27 — 👍 6    🔁 2    💬 0    📌 0

FDA pauses all infant RSV vaccine trials after rise in severe illnesses The US Food and Drug Administration (FDA) has put on hold all respiratory syncytial virus (RSV) vaccine trials involving infants (aged under 2 years) or RSV naive children aged 2-5 years, after a tria...

Agree that mRNA vaccine technology needs deeper evaluation. @fda.gov should provide further details in due course.

www.bmj.com/content/387/...

26.12.2024 14:14 — 👍 0    🔁 0    💬 0    📌 0

Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV

New work from us:
Oral vancomycin is associated with attenuation in IBD activity in people with PSC. We also studied changes in gut microbiome profile, and key transcriptomic and metabolomic features.

academic.oup.com/ecco-jcc/adv...

14.12.2024 13:18 — 👍 6    🔁 2    💬 0    📌 0

Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV

Great work by Nabil Quraishi, Palak Trivedi and many others - unravelling the positive impact of #vancomycin in #PSC #IBD by altering interactions between the host, #microbiome, and #metabolome. Now in #JCC: academic.oup.com/ecco-jcc/adv... #GastroSky

14.12.2024 11:53 — 👍 25    🔁 7    💬 0    📌 4